AtriCure (NASDAQ:ATRC) Sets New 1-Year High After Better-Than-Expected Earnings

Key Points

• AtriCure beat quarterly earnings expectations, reporting adjusted EPS of $0.17 versus the consensus estimate of a $0.06 loss, and revenue of $154.45 million versus $151.05 million expected.
• Shares reached a new 52-week high of $63.79 after the results, up from the previous close of $60.41.
• The company expects 2026 revenue of $606 million to $610 million and adjusted EBITDA of $91 million to $94 million; Needham and BTIG raised their price targets to $70.

AtriCure, Inc. (NASDAQ:ATRC - Get Free Report) shares hit a new 52-week high on Wednesday following a better than expected earnings announcement. The stock traded as high as $63.79 and last traded at $63.1830, with a volume of 90,550 shares trading hands. The stock had previously closed at $60.41.

The medical device company reported $0.17 earnings per share for the quarter, topping the consensus estimate of ($0.06) by $0.23. AtriCure had a net margin of 1.85% and a return on equity of 2.34%. The firm had revenue of $154.45 million for the quarter, compared to analysts' expectations of $151.05 million.

Key Stories Impacting AtriCure

Here are the key news stories impacting AtriCure this week:

• Positive Sentiment: AtriCure reported third-quarter adjusted earnings of $0.17 per share and revenue of $154.45 million, ahead of analyst estimates of $151.05 million in revenue. Benzinga: AtriCure analysts boost their forecasts
• Positive Sentiment: Needham raised its price target from $64 to $70 and maintained a Buy rating; BTIG also raised its target to $70, reflecting more favorable analyst expectations after the results. StreetInsider: BTIG raises AtriCure price target
• Positive Sentiment: The company projects 2026 adjusted EBITDA of $91 million to $94 million and is targeting completion of BoxX-NoAF trial enrollment by year-end, offering an earnings outlook and clinical milestone for investors to track. Seeking Alpha: AtriCure’s 2026 EBITDA outlook and trial enrollment target
• Neutral Sentiment: AtriCure expects 2026 revenue of $606 million to $610 million, broadly around the cited FactSet estimate of $606.2 million. MarketScreener: AtriCure’s 2026 revenue outlook

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the stock. Citigroup restated a "market outperform" rating on shares of AtriCure in a report on Wednesday, October 21st. UBS Group cut shares of AtriCure from a "buy" rating to a "sell" rating in a research report on Wednesday, October 21st. Citizens Jmp boosted their price target on shares of AtriCure from $52.00 to $68.00 and gave the company a "market outperform" rating in a report on Wednesday, October 21st. Zacks Research lowered shares of AtriCure from a "strong-buy" rating to a "hold" rating in a report on Monday, August 24th. Finally, Weiss Ratings upgraded shares of AtriCure from a "hold (c-)" rating to a "hold (c)" rating in a research report on Thursday, October 8th. Six research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus price target of $57.00.

Insider Activity at AtriCure

In other AtriCure news, Director Regina E. Groves sold 5,313 shares of the firm's stock in a transaction that occurred on Friday, September 11th. The shares were sold at an average price of $54.22, for a total transaction of $288,070.86. Following the sale, the director directly owned 34,546 shares in the company, valued at approximately $1,873,084.12. This trade represents a 13.33% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Salvatore Privitera sold 7,763 shares of AtriCure stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $52.50, for a total transaction of $407,557.50. Following the completion of the transaction, the insider directly owned 150,921 shares in the company, valued at approximately $7,923,352.50. The trade was a 4.89% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 30,622 shares of company stock worth $1,626,003. 4.00% of the stock is owned by company insiders.

Institutional Investors Weigh In On AtriCure

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Man Group plc acquired a new position in AtriCure during the second quarter worth $684,000. Bank of America Corp DE increased its stake in AtriCure by 13.7% in the 1st quarter. Bank of America Corp DE now owns 768,561 shares of the medical device company's stock valued at $21,927,000 after buying an additional 92,830 shares during the last quarter. WINTON GROUP Ltd bought a new stake in AtriCure during the 2nd quarter worth about $1,002,000. The Manufacturers Life Insurance Company bought a new stake in AtriCure during the 2nd quarter worth about $699,000. Finally, Jupiter Topco LLC acquired a new position in shares of AtriCure during the 2nd quarter worth about $640,000. 99.11% of the stock is currently owned by institutional investors and hedge funds.

AtriCure Stock Performance

The company has a market capitalization of $3.23 billion, a price-to-earnings ratio of 302.38 and a beta of 1.23. The stock's 50 day moving average price is $56.03 and its 200 day moving average price is $38.40. The company has a current ratio of 4.22, a quick ratio of 3.19 and a debt-to-equity ratio of 0.14.

About AtriCure

AtriCure, Inc is a medical device company that develops and sells products for the surgical treatment of atrial fibrillation (AFib) and related conditions. Its technologies are designed to support cardiac surgeons and electrophysiologists performing tissue ablation, left atrial appendage management and other procedures intended to restore or maintain normal heart rhythm.

The company's product portfolio includes the AtriClip device, which is used to exclude the left atrial appendage, along with surgical ablation systems such as the Isolator Synergy clamps and cryoablation products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.